The winding journey of biotech capital raising: deciphering the jargon
- PMID: 37451947
- DOI: 10.1016/j.tibtech.2023.06.011
The winding journey of biotech capital raising: deciphering the jargon
Abstract
Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists' mindsets and investment theses will increase the probability of securing needed capital.
Keywords: biotech; fundraising; venture capital.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests N.F., M.C., and O.B.J. are members of the investment banking team at Outcome Capital, a life sciences and healthcare specialized advisory and investment banking firm in Boston, MA, USA assisting companies in capital raising and merger and acquisition transactions. O.B.J. serves as a member of the board of directors for Elios Vision.
MeSH terms
LinkOut - more resources
Full Text Sources